First published on May 17, 2022
Introduction and Update
Why has the “Confidential Pfizer report” made public under Freedom of Information (FOI) in October 2021 not been quoted or referred to in parliamentary and public enquiries as a means to refuting the official narrative (which contends that the Covid-19 vaccine is “safe and effective”). Neither has it been the object of media coverage.
We have documented numerous public enquiries.
The evidence amply confirms that the Pfizer vaccine is a dangerous substance, resulting in deaths and adverse events. This is confirmed by the Pfizer Confidential Report released under FOI in October 2021. It come’s from the Horse’s Mouth.
Bombshell Study: Cancer Related Excess Mortality in England and Wales
A recent study on vaccine related excess mortality conducted by the team of Edward Dowd confirms the nature of the mRNA vaccine.
Dowd’s method was to analyze the number of deaths attributed to cancer in England and Wales between 2010 and 2022 [based on data] from the U.K. Office for National Statistics
He compared excess death rates, the difference between observed deaths and the baseline for expected deaths, before and after the COVID-19 pandemic.
He established a baseline of normal cancer death rates from 2010-2020 that was remarkably consistent with few deviations, he said — until the cancer death rates rose significantly in late 2021 in the U.K. following the vaccine rollout”
The table below pertains to excess deaths related to malignant neoplasm (cancerous tumor) in England and Wales, recorded in three consecutive years: 2020, 2021, and 2022 vs. a 10 year trend (2010-2019).
The data for excess mortality in 2020 (the year prior to the vaccine) are negative with the exception of “malignant neoplasm without specification of site”.
The vaccine was launched in December 2020
The upward movement in excess mortality (%) commences in 2021. The increase in excess mortality related to malignant neoplasm is tabulated for the two first years of the vaccine.
Michel Chossudovsky, Global Research, November 23, 2023